Cancer Network shared on their X/Twitter page:
“View our top 5 posts of the week:
- ODAC Approves MRD End Point in Multiple Myeloma Trials
- Updates in Breast Cancer Care From the 41st Annual Miami Breast Cancer Conference
- Sacituzumab Tirumotecan Shows Early Efficacy in Gastric/GEJ Cancers
- FDA Approves Alectinib for Early-Stage ALK-positive NSCLC
- Real-World Data Support SLNB Omission in HR+ HER2– Breast Cancer“
Source: Cancer Network/X